On August 25, 2022 Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, reported that the company will present at a number of scientific meetings taking place in September 2022, including the 14th International Conference on Osteogenesis Imperfecta (OI 2022), The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022), and the Military Health System Research Symposium (MHSRS 2022) (Press release, Quince Therapeutics, AUG 25, 2022, View Source [SID1234619485]). Meeting participation details are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
OI 2022 – August 30 to September 2, 2022, in Sheffield, United Kingdom
Abstract Title: Fracture-targeted Anabolics for Treatment of Osteogenesis Imperfecta Fractures
Presenter: Karen Smith, M.D., Ph.D. – Chief Medical Officer, Quince Therapeutics
Authors: Stewart Low1, Jeffery Nielsen1, Xinlan Lu1, Arden Shen2, Mini Thomas1
ASBMR 2022 – September 9 to September 12, 2022, in Austin, Texas
Abstract Title: Improved Spinal Fusion Through Targeted Delivery of Abaloparatide
Presenter: Mini Thomas – Senior Scientist, Quince Therapeutics
Authors: Jeffery J. Nielsen1,2, Stewart A Low 1, Mini Thomas1,Christopher Chen1, Xinlan Li1, Ephraim Mbachu1, Lina Trigg2, Madeline Tremby2, Philip S. Low2
Abstract Title: : Evaluating the Efficacy of an Acidic Oligopeptide-radioisotope Chelator Conjugate to Target and Deliver Radioactive Agents to Bone Cancers
Presenter: Da sol Jung – Graduate Student, Purdue University
Authors: Da sol Jung2, Philip S. Low2
MHSRS 2022 – September 12 to September 15, 2022, in Kissimmee, Florida
Abstract Title: Engineered Bone Fracture Targeted Parathyroid Hormone Agonist as an Effective Pharmaceutical for Accelerated Bone Repair in Mouse and Canine Models
Presenter: Mary Niedrauer – Scientist 2, Quince Therapeutics
Authors: Jeffery J. Nielsen1,2, Stewart A Low 1, Philip S. Low2
1Quince Therapeutics, West Lafayette, IN 2Purdue University, West Lafayette, IN
Quince plans to post related presentations, posters, and abstracts to Science section of its corporate website in conjunction with its participation as these respective scientific meetings.